Huange Zhu,Burong Li,Jie Lu et al.
Huange Zhu et al.
Lung cancer is one of the most common types of cancer and the leading cause of cancer-related deaths worldwide, including China. Early-stage treatment involves anatomical lung resection, while advanced stages require chemotherapy or radioth...
Single-cell analysis of lung cancer metabolism and its clinical implications [0.03%]
单细胞分析肺癌代谢及其临床意义
Xinglong Li,Guangsong Tang,Wenyue Wang et al.
Xinglong Li et al.
Background: Lung cancer is a highly prevalent and invasive malignancy, characterized by profound metabolic reprogramming as one of its key features. The advent of single-cell RNA sequencing (scRNA-seq) has allowed us to s...
Serum ZFPL1 as a clinical biomarker for diagnosis, progression tracking, and treatment response in lung cancer [0.03%]
血清ZFPL1作为肺癌诊断、病情跟踪和治疗反应的临床生物标志物
Teng Yu,Honglin Liu,Yingxuan Chen et al.
Teng Yu et al.
Objective: Zinc finger protein-like protein 1 (ZFPL1) is a key protein involved in various biological processes such as cell growth, migration, proliferation, and metabolism. It plays a significant role in the development...
Exploring the application of PD-1/PD-L1 inhibitors for ovarian cancer [0.03%]
探索PD-1/PD-L1抑制剂在卵巢癌中的应用
Xinyu Miao,Zhenpeng Wang,Dongzhen Liu et al.
Xinyu Miao et al.
Ovarian cancer remains one of the leading causes of cancer-related mortality among women worldwide. Although standard treatment regimens, including cytoreductive surgery combined with platinum-based chemotherapy, have achieved certain thera...
Pharmacoinformatics-based screening of Capparis spinosa phytocompounds against pancreatic ductal adenocarcinoma by targeting TSPAN1 protein [0.03%]
基于药理信息学的筛选刺角瓜植物化合物针对胰腺导管腺癌中TSPAN1蛋白的作用研究
Hanieh Beyrampour-Basmenj,Morteza Hadizadeh,Abolfazl Doustmihan et al.
Hanieh Beyrampour-Basmenj et al.
Background: Today, phytochemicals have garnered significant attention due to their diverse pharmacological effects against various diseases, particularly cancer. Computer-aided drug design (CADD) is a time- and cost-effec...
The long-term trends in the disease burden of acute Lymphoblastic Leukemia in China from 1990 to 2021 and projections for the next 15 years [0.03%]
中国急性淋巴细胞白血病疾病负担的长期趋势（1990-2021年）及未来15年的预测
Dameng Zhang,Shan An,Xiangyu Dong et al.
Dameng Zhang et al.
Background: This study examines the burden of acute lymphoblastic leukemia (ALL) in China from 1990 to 2021 and predicts future trends over the next 15 years. ...
miR-150 in cancer metastasis: Orchestrating migration, invasion, and angiogenesis through context-dependent mechanisms [0.03%]
miR-150在癌症转移中的作用：通过上下文依赖机制协调迁移、侵袭和血管生成
Belal Almajali,Waleed K Abdulsahib,S Renuka Jyothi et al.
Belal Almajali et al.
Metastasis, which accounts for approximately 90 % of cancer-related mortality, is driven by intricate regulatory networks that remain only partially understood. MicroRNA-150 (miR-150) has emerged as a pivotal, context-dependent regulator wi...
Neoadjuvant FOLFOXIRI for locally advanced rectal cancer: A retrospective analysis focusing on long-term anal preservation [0.03%]
新辅助FOLFOXIRI治疗局部晚期直肠癌：长期保肛的回顾性分析
Ryohei Shoji,Fuminori Teraishi,Yuki Matsumi et al.
Ryohei Shoji et al.
To investigate the safety and efficacy of FOLFOXIRI as neoadjuvant chemotherapy (NAC) for locally advanced rectal cancer (LARC). The outcomes of preoperative and perioperative treatments, as well as long-term outcomes, were retrospectively ...
Cutting-edge drug resistance analysis of major cancers at single-cell level [0.03%]
基于单细胞水平的主要癌症的最新药耐受性分析方法
Tianyu Liu,Zhiyuan Cao,Wenxin Long et al.
Tianyu Liu et al.
Drug resistance, which means cancer cells are resistant to treatments, has been a major problem in cancer treatment. While drug tolerance which defines the long survival of cancer cells could be a possible reason, analyzing the sources and ...
Comprehensive review on outcomes from Phase 3 clinical trials of drugs in multiple myeloma [0.03%]
治疗多发性骨髓瘤药物III期临床试验结果的综合回顾分析
Sandeep Singh,Vivek Uttam,Shafiul Haque et al.
Sandeep Singh et al.
Multiple myeloma (MM) is a clonal plasma cell malignancy characterized by clinical heterogeneity, high relapse rates, and eventual drug resistance despite advances in therapy. Over the past two decades, phase 3 clinical trials have redefine...